Cowen and Company’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Cowen and Company’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,200	Closed	-$143K	–	775
2021 Q4	$143K	Buy	+3,200	New	+$497K	0.01%	334
2021 Q2	–	Sell	-29,600	Closed	-$409K	–	738
2021 Q1	$409K	Buy	+29,600	New	+$5.86M	0.03%	203
2020 Q4	–	Sell	-15,400	Closed	-$66K	–	541
2020 Q3	$66K	Buy	15,400 +8,500	+123%	+$1.16M	0.01%	282
2020 Q2	$10K	Buy	6,900 +2,200	+47%	+$213K	﹤0.01%	359
2020 Q1	$195K	Sell	4,700 -10,000	-68%	-$897K	0.04%	197
2019 Q4	$88K	Buy	+14,700	New	+$1.42M	0.01%	273

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cowen and Company's MRTX Position: Q1 2024 in Review

Cowen and Company sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 123,783 shares — an estimated $7.27M sold.

Cowen and Company first reported a position in MRTX in Q4 2019 and held it in 6 quarters. The position peaked at $7.27M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Cowen and Company reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Cowen and Company sold 123,783 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $7.27M.
Cowen and Company first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 6 quarters.
Cowen and Company's Mirati Therapeutics, Inc. Common Stock position peaked at $7.27M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.